Now that mRNA-based vaccines and gene therapies have been proven, how do we as an industry take the next step? How do we produce the large quantities of high-quality viral vectors and plasmids needed to propel other candidates forward?
Innovation has a key role to play. Here we’ll describe modern purification technology for plasmid DNA and adeno-associated virus (AAV) that’s poised to improve productivity and speed in both processes. We’ll compare this new tech with legacy methods to show what’s possible.
In this webinar, you will learn about:
Peter is Global Product Manager at Cytiva with responsibility for products tailored for downstream processing of Advanced Therapy Medicinal Products. He is based in Uppsala, Sweden. Peter earned is PhD in Neurochemistry from Stockholm University in 2009. He has been with GE since 2003, primarily working in various roles associated with oligonucleotide synthesis and purification. Since GE’s acquisition of Puridify, Peter has the business responsibility to develop products based on the Fibro technology to complement Cytiva’s portfolio of chromatography resins and to develop it further to generate tailored solutions for the manufacture of Advanced Therapy Medicinal Products.
Henrik is Director of Strategic Technologies at Cytiva, with a specific focus on Downstream purification of biopharmaceuticals. He is based in Uppsala. Henrik earned his Ph.D. in synthetic organic polymer chemistry from the Royal Academy of Engineering (KTH), Sweden and post-doc training from UC Berkeley in California, USA. He joined Amersham Pharmacia Biotech in August 2000, which was acquired by by GE Healthcare in 2004. He has devoted his career to the design and development of several purification products enabling the manufacturing of life changing drugs on the market.
Henrik started as a Senior Scientist in the R&D chromatography resin department and later transferred into the role of Product Manager for several key products such as the Protein A portfolio. For more than ten years, he headed and expanded the custom consumables organization offering customization within segments such as Chromatography resins, Ready To Process columns, Small scale pre-packed columns and Primer supports for oligo synthesis. During his time in the custom consumables organization, he made valuable contributions to product design and development, bringing more than 30 key products to the market, which now are a part of the Cytiva downstream offering.
Mats is the Customer Applications Director, Life Sciences, Cytiva. He has more than 25 years of experience in the field of biotechnology. He holds a PhD in Immunology, Cell and Molecular Biology from the Karolinska Institute, Stockholm, Sweden and extensive post-doc training at the MRC Clinical Sciences Centre, Imperial College School of Medicine in London, UK. In his industrial career Mats has had positions as scientist, team manager and VP at Pharmacia, AstraZeneca and smaller biotech companies. In his previous function, Mats was managing both the Cell line and Upstream Process Development teams at a major biotech company. In his current role, Mats works across different viral vector and vaccine application projects as well as general upstream topics, focusing on customer support, applicability of new technologies and manufacturing solutions.
If you would also like to sign up to access articles from Immuno-Oncology Insights - one of the other great titles from Bioinsights, please tick the box below.
As you are already a member of Immuno-Oncology Insights (also from Bioinsights), all you need to do is log in using your Immuno-Oncology password and tick the box below to become a member of Cell and Gene Therapy Insights.
You are already a member of Cell and Gene Therapy Insights (from Bioinsights). If you would also like to become a member of Immuno-Oncology Insights , you can simply log in with your Cell and Gene Therapy Insights Insights password and tick the box below.
You are already a member of Immuno-Oncology Insights (from Bioinsights). If you would also like to become a member of Cell and Gene Therapy Insights, you can simply log in with your Immuno-Oncology Insights password and tick the box below.